Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CCR4 | P51679 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200203 | 1.00 | CD274 (0.51) | CD274PDCD1CYP1A2CYP2C19MEN1 | |
| SCHEMBL2032294 | 0.86 | CYP1A2 (0.51) | CD274PDCD1CYP1A2CYP2C19SPHK1 | |
| SCHEMBL1817183 | 0.86 | CYP1A2 (0.51) | CD274PDCD1CYP1A2CYP2C19SPHK1 | |
| SCHEMBL3148407 | 0.86 | CYP1A2 (0.51) | CD274PDCD1CYP1A2CYP2C19SPHK1 | |
| SCHEMBL1819248 | 0.86 | CYP1A2 (0.60) | CD274PDCD1CYP1A2CYP2C19SPHK1 | |
| SCHEMBL2587055 | 0.86 | CYP1A2 (0.60) | CD274PDCD1CYP1A2CYP2C19SPHK1 | |
| SCHEMBL1972076 | 0.86 | CYP1A2 (0.60) | CD274PDCD1CYP1A2CYP2C19SPHK1 | |
| SCHEMBL15652882 | 0.85 | ALDH1A1 (0.54) | CD274PDCD1CYP1A2CYP2C19SPHK1 | |
| SCHEMBL1819133 | 0.85 | IDO1 (0.53) | CD274PDCD1CYP1A2CYP2C19KMT2A | |
| SCHEMBL1819166 | 0.85 | CD274 (0.53) | CD274PDCD1CYP1A2CYP2C19SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| EP-3154568-A1 | NON-CANONICAL INSULINS AND THEIR USES | California Institute of Technology (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191705-A1 | NON-CANONICAL INSULINS AND THEIR USES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-12-17 | — | — | WO | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | claimed |
| US-7884074-B2 | Compounds and methods for prevention and/or treatment of inflammation using the same | Ikaria Development Subsidiary Two, LLC (US) | 2011-02-08 | — | — | US | claimed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | claimed |
| US-20100099602-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | US | claimed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | claimed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | claimed |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | claimed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | claimed |
| EP-4153310-B1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 PHARMA GMBH (AT) | 2026-02-18 | — | — | EP | disclosed |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES INC. | 2025-08-07 | — | — | US | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | CD274 324/4885PDCD1 1581/4885CYP1A2 4240/4885 |
| US-20100099602-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | HIF1AN, HIF1A, EGLN3 | CD274 4744/4885PDCD1 4725/4885CYP1A2 2264/4885 |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | CD274 4744/4885PDCD1 3844/4885CYP1A2 2895/4885 |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NGLY1, GHRHR, GHSR | CD274 4492/4885PDCD1 4740/4885CYP1A2 2694/4885 |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NPR3, RXFP3, RXFP1 | CD274 3848/4885PDCD1 4395/4885CYP1A2 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.